Major Psychedelic Stock Downward Trend Continues

psychedelic stocks

There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and here is how its constituents performed this past week, in descending order, since the end of September (i.e. 3 weeks) and since the end of August (7 weeks):

  1. Allied Corp. (ALID): UP 6.0% this past week; UP 17.8% in last 3 weeks; UP 23.3% in the last 7 weeks
    • Has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder.
  2. Compass Pathways (CMPS): UP 1.3% this past week; DOWN 10.7% in last 3 weeks; DOWN 42.9% in the last 7 weeks: 
    • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
  3. Zynerba (ZYNE): DOWN 2.0% this past week; DOWN 8.2% in last 3 weeks; DOWN 40.2% in the last 7 weeks
    • Is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery.
  4. Mind Medicine (MNMD): DOWN 3.1% this past week; DOWN 20.0% in last 3 weeks; DOWN 75.6% in the last 7 weeks
    • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
    • Underwent a 1-for-15 reverse stock exchange on August 29th.
  5. Atai (ATAI): DOWN 5.0% this past week; DOWN 13.6% in last 3 weeks; DOWN 34.4% in the last 7 weeks
    • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
  6. Seelos (SEEL): DOWN 6.6% this past week; DOWN 17.5% in last 3 weeks; UP 1.2% in the last 7 weeks
    • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
  7. GH Research (GHRS): DOWN 9.6% this past week; DOWN 7.9% in last 3 weeks; DOWN 32.7% in the last 7 weeks
    • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
  8. Cybin (CYBN): DOWN 14.0% this past week; UP 2.1% in last 3 weeks; DOWN 53.8% in the last 7 weeks:
    • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

In total, the munKNEE Psychedelic Drug Stock Index went DOWN 4.6% this past week, has gone DOWN 19.6% in the last 5 weeks and DOWN 45.5% since the end of August (7 weeks).

Six other psychedelic companies are primarily focused on the development, expansion and operation of ketamine-assisted therapy (KAT) clinics to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction and substance abuse withdrawal, and depression. They are identified below with a description of each of their commercialization developments:

  1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF)
    • Is concentrating on the treatment of Alcohol Use Disorder (AUM)
      • has 3 KAT clinics, 2 in the U.K. and 1 in Norway and
      • is developing MDMA-assisted therapy for AUM
    •  Is also in the process of developing KAT for Gambling Disorder
    • Go here for the company's latest quarterly (Q2) financial results.
  2. Delic Corp. (CSE: DELC|OTCQB: DELCF)
    • Has 13 ketamine-assisted therapy (KAT) clinics in the U.S.
  3. Field Trip Health and Wellness Ltd. (TSXV:FTHW|OTCQB:   FTHWF)
    • Is concentrating on therapies for the treatment of resistant depression, post-traumatic stress disorder and disorders affecting the central nervous systems;
    • Operates KAT clinics in Canada (3), the U.S. (8) and Europe (1)
  4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF)
    • has 3 KAT clinics in Canada;
    • has the ability to undertake treatments using psilocybin and MDMA in Canada as authorized by Health Canada's Special Access Program;
    • Has 6 KAT clinics in Utah and 2 in Arizona
  5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB:   RVLWF)
    • Has 10 KAT clinics in 6 states and 9 options on other clinics
  6. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)
    • Is concentrating on the treatment of Opioid Use Disorder using ibogaine which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the US) facilitating research and development toward medicalization

The  above psychedelic-assisted therapy clinic stocks went DOWN 17.1%, on average, this past week, went DOWN 23.2% in the past 3 weeks and has gone DOWN 41.7% since the end of August.

More By This Author:

Largest Canadian Cannabis LPs Advanced 4.5% This Week
Major American Cannabis MSOs Up 14.4% This Week
Plant-Based Food Stocks Correlate Loosely With Their Stock Performances

Visit and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.